Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma

Figures & data

Table 1 Descriptive statistics of the preinjection and follow-up data

Variable	Minimum	Maximum	Mean	Standard deviation
Age	50.00	65.00	58.4000	4.4414
VA preinjection	0.05	0.40	0.1135	9.928E-02
IOP preinjection	30.00	50.00	41.4500	5.8891
VA at 12 months	0.05	0.70	0.2310	0.1933
IOP at 6 months	14.00	30.00	19.3000	5.4974
IOP at 12 months	14.00	28.00	17.7000	3.7290

Abbreviations: IOP, intraocular pressure; VA, visual acuity.

Table 2 Recurrence of neovascularization over the follow-up period

Recurrence	4 months	8 months	12 months
Yes	5	14	0
No	15	6	20

Table 3 Intraocular pressure (IOP) control and antiglaucoma medications used over the follow-up period

Variable	Preinjection	6 months	12 months
IOP	41.45	19.3	17.7
Controlled cases	None	15	18
Cases received beta blockers		2	2
Cases received combined beta blockers and CAIs		1	2

Abbreviations: CAI, carbonic anhydrase inhibitors; IOP, intraocular pressure.

Table 4 The difference in the VA and IOP over the follow-up period

Variable	t	df	Sig.
VA preinjection and at 12 months	−4.252	19	.000
IOP preinjection and at 6 months	13.650	19	.000
IOP preinjection and 12 months	16.495	19	.000

Abbreviations: IOP, intraocular pressure; VA, visual acuity.